The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs).
 
Shalini Subramaniam
No Relationships to Disclose
 
Guy C. Toner
Consulting or Advisory Role - Amgen (Inst); Bayer (Inst)
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Medivation (Inst); Medivation (Inst)
 
Martin R. Stockler
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Tilray (Inst)
Travel, Accommodations, Expenses - Medivation/Pfizer
 
Andrew James Martin
No Relationships to Disclose
 
Farzana D. Pashankar
No Relationships to Disclose
 
A. Lindsay Frazier
Stock and Other Ownership Interests - Decibel Therapeutics
Consulting or Advisory Role - Decibel Therapeutics
 
Danish Mazhar
Stock and Other Ownership Interests - Genesis Cancer Care
 
Kate Ford
No Relationships to Disclose
 
Euan Thomas Walpole
Consulting or Advisory Role - Novartis
Research Funding - MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
 
Amanda Gwendolyn Stevanovic
No Relationships to Disclose
 
David Wyld
No Relationships to Disclose
 
Simon Troon
Research Funding - Astellas Pharma (Inst); pfizer (Inst)
 
Fritha J. Hanning
Employment - Canopy Cancer Care
Leadership - Canopy Cancer Care
Honoraria - Merck Sharp & Dohme
Consulting or Advisory Role - Merck Sharp & Dohme
Travel, Accommodations, Expenses - Roche
 
Alison Jane Birtle
Honoraria - Janssen-Cilag
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; Bayer Schering Pharma; Janssen Oncology; Roche; Sanofi
 
Matthew James Wheater
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; Delcath Systems; MSD; Novartis; Pfizer; Pierre Fabre
Consulting or Advisory Role - Bristol-Myers Squibb; Healthcare at Home; Novartis
Research Funding - AVEO (Inst); GlaxoSmithKline/Novartis (Inst); GlaxoSmithKline/Novartis (Inst); MSD (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD
 
Robert A. Huddart
Leadership - Cancer clinic london Limited liability partnership
Honoraria - Janssen Oncology
Consulting or Advisory Role - Bristol-Myers Squibb; Janssen Oncology; Merck Sharp & Dohme; Nektar; Roche
Speakers' Bureau - MSD; Roche
Research Funding - Bristol-Myers Squibb (Inst); Janssen (Inst); Merck Sharp & Dohme (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Royalties for dug discovery from Janssen (Inst)
Travel, Accommodations, Expenses - Janssen Oncology; MSD Oncology; Roche/Genentech
 
Jeff D. White
No Relationships to Disclose
 
Sheri L. Spunt
Research Funding - Loxo (Inst)
 
Peter S. Grimison
Research Funding - ASLAN Pharmaceuticals (Inst); Boston Biomedical (Inst); Eisai (Inst); Eisai (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); Halozyme (Inst); Medimmune; MSD (Inst); Pfizer (Inst); Pfizer (Inst); Specialised Therapeutics; Tigermed (Inst); Tilray (Inst); Zucero Therapeutics